HomeENGLISH MAGAZINEMultiple myeloma: a drug might become a stable maintenance ruler

Multiple myeloma: a drug might become a stable maintenance ruler

Myeloma is a cancer of the plasma cells and it can affect several areas of the body, such as the spine, skull, pelvis and ribs. Current treatment usually involves chemotherapy and a stem-cell transplant. Hope has emerged for patients with this serious type of bone marrow cancer, as new research into a therapeutic drug has revealed improved outcomes and survival rates. In the largest study of its kind, researchers at Newcastle University, UK, have led national research into the treatment of patients with newly diagnosed myeloma. The results, published online today by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide (also known as Revlimid®), compared to those not receiving it. Findings of the study identified that long-term therapy with lenalidomide doubles remission duration and also improves survival in younger patients by almost 8%. Professor Graham Jackson, from the Northern Institute for Cancer Research at Newcastle University, and a Consultant Haematologist at Newcastle’s Freeman Hospital, led the UK-wide study. The Myeloma XI seven-year study involved more than 4,000 patients in 110 hospitals in the UK and was funded primarily by Cancer Research UK, with support from Myeloma UK and a number of educational grants.

As part of the study, a total of 1,137 newly diagnosed patients were randomly assigned to lenalidomide maintenance therapy and 834 patients to observation – this was after they completed their initial treatment. The clinical trial was run through the Clinical Trials Research Unit at the University of Leeds and the research involved experts from hospitals around the UK. Patients were randomly assigned (1:1 from Jan 13, 2011, to Jun 27, 2013, and 2:1 from Jun 28, 2013, to Aug 11, 2017) to lenalidomide maintenance (10mg orally on days 1-21 of a 28-day cycle) or observation, and stratified by allocated induction and intensification treatment The results show that lenalidomide can prolong the average remission time by more than two years in younger patients and by well over a year in older, less fit patients. It reduced the risk of progression or death by more than 50% in both groups. Serious adverse events were reported in 494 (45%) of 1097 patients receiving lenalidomide compared with 150 (17%) of 874 patients on observation. Fourhundred and sixty deaths occurred during maintenance treatment, 234 (21%) in the lenalidomide group and 226 (27%) in the observation group, while no deaths in the lenalidomide group were deemed treatment related.

The results confirm the findings of three much smaller studies which showed that after stem-cell transplantation, lenalidomide reduces the risk of disease progression or death by 50% compared with placebo or no treatment. Dr Jackson said: “This is a major breakthrough as it shows that the long-term use of lenalidomide significantly improves the time myeloma patients stay in remission after initial therapy. It is a huge step and, importantly, identifies that for younger patients lenalidomide improves their overall survival for this difficult-to-treat bone marrow cancer. Our research highlights that lenalidomide should be considered for newly diagnosed patients following stem-cell transplantation”. Professor Gordon Cook, Clinical Director at the Leeds Institute of Clinical Trials Research at the University of Leeds, and co-author of the paper, believes lenalidomide should be available on the NHS: “Our results confirm lenalidomide can significantly prolong the lives of people living with multiple myeloma in the largest trial to date. The manageable safety profile of this drug and the encouraging results in subgroup analyses of patients across all cytogenetic risk groups, support further investigation of maintenance lenalidomide in this setting. This treatment is not yet available on the NHS for this group of patients and this represents an unmet need”.

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Jackson GH, Davies FE et al. Lancet Oncol. 2018 Dec 14.

Mateos MV, de la Calle VG. Lancet Oncol. 2018 Dec 14.

Paquin AR et al. Blood Cancer J. 2018 Dec 11; 8(12):125.

Manasanch EE et al. Lancet Haematol. 2018; 5(12):628-40.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -